Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Acquires 20,000 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 16th. The shares were acquired at an average cost of $4.22 per share, for a total transaction of $84,400.00. Following the purchase, the chief executive officer now owns 2,315,731 shares of the company’s stock, valued at $9,772,384.82. This represents a 0.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Wednesday, March 5th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average cost of $5.02 per share, for a total transaction of $50,200.00.
• On Friday, February 28th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average cost of $4.76 per share, for a total transaction of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Trading Up 3.0%

Shares of VNDA opened at $4.44 on Wednesday. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $6.75. The company has a market cap of $261.67 million, a P/E ratio of -13.88 and a beta of 0.69. The company’s fifty day simple moving average is $4.42 and its 200-day simple moving average is $4.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. The business had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its holdings in shares of Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after purchasing an additional 227,428 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 220.0% in the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after purchasing an additional 1,470,898 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock worth $6,949,000 after purchasing an additional 24,483 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Vanda Pharmaceuticals by 13.5% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company’s stock worth $4,267,000 after purchasing an additional 110,262 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in shares of Vanda Pharmaceuticals by 1.4% in the fourth quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company’s stock worth $3,481,000 after purchasing an additional 9,840 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.